Technology | September 10, 2014

Varian to Debut InSightive Analytics Interactive Dashboard and Visualization Solution for Oncology at ASTRO

Users of Varian's Aria oncology information system (OIS) will be introduced to a new tool, InSightive Analytics, at ASTRO 2014.

Users of Varian's Aria oncology information system (OIS) will be introduced to a new tool, InSightive Analytics, at ASTRO 2014.

September 10, 2014 — Varian Medical Systems will introduce InSightive Analytics, a new interactive dashboard and data visualization tool for oncology professionals, at the annual meeting of the American Society for Radiation Oncology (ASTRO) Sept. 14-17 in San Francisco.

InSightive Analytics will enable users of Varian's Aria oncology information system (OIS) to quickly access, organize and analyze data captured during clinical and administrative operations in radiation oncology. Prebuilt templates within the tool allow quick organization and display of key healthcare metrics across the hospital, clinic or network. Data can be collected on payer mix, referral sources, patient zip codes, operational performance, patient volume, case mix per treatment unit, physician volumes and more. Data can be benchmarked against historical data for trend analysis, and reports can be exported as Excel or Adobe PDF files and email messages.

"Aria is a robust practice management system and electronic medical record with a tremendous amount of information that can be mined and analyzed to enhance the quality of care and the efficiency of clinical operations at any given site," said Sukhveer Singh, vice president of Varian's Oncology Continuum Solutions. "Many customers use Aria to become paperless clinics, so all the information that once went into paper charts is now entered into the Aria system. Aria also offers many interfaces for importing data from other hospital information systems, resulting in a very rich resource that, up to now, was difficult to mine for actionable knowledge. InSightive Analytics provides access to this data, making it visible and useful."

InSightive Analytics will enable users to discover important patterns and trends quickly so they can make more informed data-driven decisions. Users can preprogram dashboards to generate reports on a routine schedule. Graphs and tables can be exported for presentation. According to Singh, it will be especially useful for cancer center administrators who need to manage resources.

"Often departmental administrators are trying to make important decisions based on Medicare billing data that might be weeks or months old, and often only includes some 40-60 percent of the patient population," said Singh. "With InSightive Analytics drawing directly from the Aria database as patients receive their treatments, it will be possible to aggregate up-to-date information and use it to identify opportunities and strategies for enhancing clinical, operational and financial outcomes."

"We know that today's cancer care professionals, like all medical practitioners, are under pressure to control healthcare costs while improving coordination and quality outcomes. Having access to the right information at the right time has never been more essential," said Kolleen Kennedy, president of Varian's Oncology Systems business. "As a tool that leverages new developments in informatics and big data mining, InSightive Analytics is designed to help our customers deliver high-quality, evidence-based care."

InSightive Analytics is a work in progress and not yet available for sale.

For more information: www.varian.com

Related Content

A special issue of the Journal of Medical Imaging and Radiation Sciences features stories about the interpersonal skills beyond the technical aspects to care for and guide patients through medical imaging and radiation therapy procedures

Image courtesy of Canon

News | Patient Engagement | August 11, 2020
August 11, 2020 — "I went into the MRI
Global radiotherapy market revenue is set to expand from $7,222.4 million in 2019 to $17,194.4 million by 2030, at an 8.4% CAGR between 2020 and 2030, the key factor driving the market growth is the increasing number of cancer cases, according to the report published by P&S Intelligence.

Image courtesy of Elekta

News | Radiation Therapy | August 06, 2020
August 6, 2020 — Global ...
Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly welcomes Siemens Healthineers AG’s acquisition of a 100 percent stake in Varian Medical Systems, Inc., a U.S. company active in the area of cancer research and therapy.

Getty Images

News | Radiology Business | August 03, 2020
August 3, 2020 — Siemens AG is continuing to rigorously execute its Vision 2020+ strategy and therefore expressly wel
JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

Table 1. JAMA Oncol. Published online  July 30, 2020. doi:10.1001/jamaoncol.2020.2783

News | Coronavirus (COVID-19) | July 31, 2020
July 31, 2020 — An article published in JAMA...
It has been estimated that the overwhelming focus on COVID-19 could cause up to 35,000 excess cancer deaths in the UK during the next 12 months, and  Zegami, the Oxford University data visualization spin-out which has worked on several projects focused on the detection, diagnosis, or management of cancer, is calling for greater use of technology to speed up the process of diagnosis and treatment.

Getty Images

News | Radiation Oncology | July 29, 2020
July 29, 2020 — It has been estimated that the overwhelming focus on...
In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.  http://jnm.snmjournals.org/content/early/2020/07/16/jnumed.120.249748.full.pdf+html

In I-131 cancer therapy, decay events damage sensitive DNA within a tumor cell nucleus, causing catastrophic single and double strand breaks. Clinical use of antibody-delivered Auger emitters could open a window for the targeted destruction of extracellular COVID-19 virions, decreasing the viral load during active infection and potentially easing the disease burden for a patient. View all figures from this study.

 

News | Coronavirus (COVID-19) | July 22, 2020 | Dave Fornell, Editor
July 22, 2020 — One of the first studies has been published that looks at the use of...
World's largest radiation oncology meeting will offer full conference on interactive platform October 25-28, 2020
News | ASTRO | July 09, 2020
July 9, 2020 — Registration opens today for the American Society for Radiation Oncology's (...
Radiotherapy has been used to treat cancers for more than a century and continues to be utilized in cancer treatment plans today. Since the introduction of radiotherapy, clinicians have been working tirelessly to further refine treatments to better target cancer.
Feature | Radiation Therapy | July 06, 2020 | By Yves Archambault
Everything has room for improvement, right? Right. When it comes to cancer care, it is no different.